Biotechnology company OSE Immunotherapeutics has received €10.7m in public funding as part of the ‘Capacity Building’ call for projects, operated on behalf of the French government by Bpifrance. The funding will further the development of CoVepiT, the company’s multi-variant Covid-19 vaccine, which is currently in a Phase I clinical trial. CoVepiT is a second-generation, multi target, multi-variant vaccine that demonstrated during preclinical studies an ability to activate T cell defences through CD8 T-cell multi-epitope responses for long-term T memory cell immunity.
Indian biopharmaceutical company Biological E. is set to produce Johnson & Johnson’s (J&J) Covid-19 vaccine, alongside its own vaccine candidate, to help India boost the overall supply of vaccines amid a shortage in the country. The infrastructure and production plants for both the vaccines will be separate, according to Biological E. managing director Mahima Datla. Biological E. is planning to contract-manufacture around 600 million doses a year of the J&J vaccine. However, the Indian government did not factor in any domestic production of the J&J jab this year in a recently-released vaccine output list.
Canadian biotechnology company Mountain Valley MD has received third-party Bio Safety Level 4 (BSL-4) lab study results from a recent Covid-19 viral clearance study conducted with Ivectosol. The trial showed that a single dose of 2.5mg per kg of Ivectosol proved to be effective at interfering with viral replication and driving viral clearance of the original B.1.1.7 Covid-19 variant. Tests revealed the same antiviral effect at 5uM Ivectosol concentration after 24 and 48 hours respectively against all three variants tested, including the original B.1.1.7 variant, the P.1 Brazil variant, and the South African B.1.351 variant.